Clinical trials: Malaria, completed
Plasmodium Falciparum Infection
PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States
This phase I trial of the replication-intact PfSPZ Challenge vaccine given under CQ cover will enroll 28 healthy volunteers to receive PfSPZ or placebo, as well as suppressive doses of chloroquine (CQ)on varying schedules.
- Trial name
- NCT02773979
- Testing
- Chloroquine, PfSPZ (NF54) Challenge
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Neurological Disorders, Cerebral Malaria
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
The impact of neurological disorders is enormous worldwide, and it is increased in poor settings, due to lack of diagnosis and treatment facilities as well as delayed management.
- Conditions
- Neurological Disorders, Cerebral Malaria, Bacterial Meningitis, Central Nervous System Tuberculosis
- Trial name
- Nidiag-Neuro (NCT01589289)
- Testing
- Immunochromatographic HAT tests (DSD), Card Agglutination Trypanosoma Test, TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)
- Where
- Democratic Republic of the Congo
- Volunteers
- 352 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria
Evaluation of Insecticide Treated Nets and Wall Liners for the Prevention of Malaria
The purpose of this study is to determine whether insecticide treated wall liners, in combination with insecticide treated nets, reduce the incidence of malaria infections compared to insecticide treated nets alone.
- Trial name
- MTC-ITWL (NCT01043796)
- Testing
- Insecticide treated nets and wall liners, Insecticide treated nets alone
- Where
- Kenya
- Volunteers
- 1,730 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
This is Cohort A1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07235020)
- Testing
- INE963
- Where
- 6 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
Malaria: Relative Bioavailability and Food Effect of DSM265
Phase 1 study designed to evaluate the relative bioavailability of a single dose of a test formulation, DSM265-TPGS 34% SDD powder in comparison with a reference DSM265 25% SDD powder formulation used in early clinical trials.
- Trial name
- NCT03637517
- Testing
- DSM265-TPGS 34% SDD, 400 mg fasted, DSM265-TPGS 34% SDD, 400 mg fed, DSM265 25% SDD, 400 mg fasted
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Instantaneous Clearance
Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine
Plasmodium falciparum resistance against artemisinins has been confirmed in South-East Asia and it is expressed phenotypically as a slow rate of parasite clearance.
- Trial name
- PCT (NCT01998295)
- Testing
- Artemether/lumefantrine
- Where
- Tanzania
- Volunteers
- 45 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Malaria
Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet
The primary objective of this study is to determine the bioequivalence of the combination of pyronaridine and artesunate (180:60mg) to-be-marketed tablet to the clinical trial reference tablet administered as a single total dose…
- Trial name
- NCT00682630
- Testing
- pyronaridine artesunate clinical trial reference tablets, pyronaridine artesunate to-be-marketed tablets
- Where
- Switzerland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2
The purpose of this study is to assess the safety, immunogenicity and efficacy of the candidate malaria vaccines ChAdOx1 LS2 and MVA LS2. Healthy adult volunteers will be recruited and vaccinated in Oxford.
- Trial name
- NCT03203421
- Testing
- ChAdOx1 LS2, MVA LS2
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Falciparum Infection
Malaria Challenge With NF54 Strain
The purpose of this study is to determine how many infected mosquito bites are required to reliably give volunteers a case of malaria. It is expected that volunteers will develop malaria and may have symptoms.
- Trial name
- NCT00744133
- Testing
- NF54 P. falciparum isolate
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children
This study will investigate the safety and immunogenicity of 2 candidate malaria vaccines administered according to 3 different vaccination schedules in 5 to 17 months old Ghanaian children.
- Trial name
- NCT00360230
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Rabipur
- Where
- 2 sites in Ghana
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vivax Malaria
Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan
This is an open label two-arm randomized prospective study of two treatments for P. vivax malaria. Patients meeting study inclusion criteria will be enrolled and allocated either chloroquine alone or chloroquine plus primaquine…
- Trial name
- VRA (NCT01178021)
- Testing
- Chloroquine, Chloroquine/Primaquine
- Where
- 3 sites in Afghanistan
- Volunteers
- 593 people
- Sponsor
- University of Oxford
Malaria, Falciparum
Chloroquine and Amodiaquine for Treatment of Malaria in Children
This study will evaluate the efficacy of the treatment recommended by the National Malaria Programme in Guinea-Bissau as compared to a higher dose of chloroquine and to another anti-malarial drug, amodiaquine.
- Trial name
- NCT00137514
- Testing
- chloroquine, amodiaquine
- Where
- Guinea-Bissau
- Volunteers
- 720 people
- Sponsor
- Bandim Health Project
Malaria, Falciparum
A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants
The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.
- Trial name
- NCT06171113
- Testing
- GSK4024484C
- Where
- United Kingdom
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Falciparum Malaria
A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects
The study will determine if amodiaquine tablet (Pfizer), an antimalaria agent, is pharmaceutically equivalent to a comparator product (Arsuamoon-Guilin China).
- Trial name
- NCT00894660
- Testing
- Amodiaquine (Test), Amodiaquine (Comparator)
- Where
- Singapore
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malaria
Anti-Malarial Drug Resistance in Cameroon
The project is a three-armed study designed to evaluate the efficacy of amodiaquine(AQ), sulphadoxine-pyrimethamine(SP) and(AQ+SP) in three sites in Cameroon that differ in their baseline characteristics for malaria.
- Trial name
- NCT00146718
- Testing
- Amodiaquine and Sulphadoxine/Pyrimethamine
- Volunteers
- 755 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Cure Rate
A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with acute P. falciparum infection after single dose with KAE609 at 75 mg, 150mg, 225mg and 300mg/day
- Trial name
- NCT01860989
- Testing
- KAE609
- Where
- 4 sites in Thailand, Vietnam
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Impact of Malaria on Pregnant Women in Ouelessebougou, Mali
Background: Malaria is a serious disease. It is passed by infected mosquitoes. In many parts of Africa, malaria continues to be the main cause of death in young children and pregnant women.
- Trial name
- NCT02974608
- Where
- Mali
- Volunteers
- 7,691 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Study of Factors Involved in Resistance to Severe Malaria
This study will examine whether resistance to severe malaria is associated with weakening of a specific immune response (TLR-mediated pro-inflammatory cytokine response).
- Trial name
- NCT00368810
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria
This is a bi-centric phase IIIb, randomized, open label, 3-arm clinical trial performed to investigate the impact of retreatment with an Artemisinin-Based Combination (ACT), for example Arthemeter-Lumefantrine (AL) in Uganda (Ug)…
- Trial name
- QuinAct (NCT01374581)
- Testing
- Artemether/Lumefantrine, Artesunate/Amodiaquine, Quinine + Clindamycin
- Where
- 2 sites in Republic of the Congo, Uganda
- Volunteers
- 2,117 people
- Sponsor
- Universiteit Antwerpen
Malaria
A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali
Plasmodium falciparum (Pf) malaria remains a major cause of morbidity and mortality worldwide. A malaria vaccine would contribute towards efforts to control and eliminate malaria.
- Trial name
- NCT01322581
- Where
- Mali
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.